Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
113 evidence topics · 68 sources
AXPAXLI (axitinib intravitreal implant)
Neovascular age-related macular degeneration
- Manufacturer
- Ocular Therapeutix
- Regulatory submission
- NDA planned for the fourth quarter of 2026
- Launch
- Anticipated in 2027
- Last updated